The FDA has issued an alert about a potentially high-risk issue involving models of Boston Scientific’s Watchman Access Systems, which are used to provide vascular and transseptal access during implantation of left atrial appendage closure devices.
The alert comes after Boston Scientific sent a letter July 30 to affected customers, recommending updates to instructions for use due to risk of air embolism during procedures, according to an Aug. 6 FDA news release
The devicemaker found a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation.
Boston Scientific reported 120 serious injuries and 17 deaths.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.